12/31/2022 0 Comments Sensei biotherapeutics![]() ![]() Prior to this, he held multiple roles of increasing responsibility across investment banking, buy-side transactions, sell-side transactions, venture creation, and has both strategy and operational experience contributing to value creation from novel science. Gallagher joins Sensei from Binney Street Partners, where he served as managing director supporting repeat entrepreneurs and venture funds to build, partner and transact biotech companies. ![]() ![]() Gallagher has nearly 20 years’ experience in pharmaceuticals and biotech, having played a material role in transactions and value creation for public and private companies, including numerous Flagship Pioneering portfolio companies, Nuvation Bio, Walking Fish Therapeutics, Radius Health, AbbVie and multiple investment banking clients. “We’re thrilled to add him to our leadership team at a pivotal moment as we work to optimize both of our platforms and advance key programs towards important milestones.” He has worked across the biotechnology, Big Pharma, venture and banking sectors and has a track record of tailoring partnerships and transactions to build value,” said John Celebi, president and chief executive officer of Sensei Biotherapeutics. ![]() “Patrick is an accomplished biotech executive who brings significant strategic and transactional expertise to Sensei. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of Patrick Gallagher, MBA, MPH, as chief business officer. “With experienced management and scientific teams, Sensei is well positioned to become a leader in next generation of immune-oncology therapeutics,” Cambrian Biopharma CEO James Peyer said in a statement.Sensei Biotherapeutics, Inc. This initial data from 9 patients provides us with the rationale to continue exploring its safety and efficacy in 1 st and 2 nd line SCCHN patients.įuture Ventures, Christian Angermayer’s Apeiron Investment Group, and Presight Ventures also chipped in to the round. To date, we have observed promising clinical activity that is correlated with immune response for SNS-301, including a partial response in a patient with PD-L1-negative disease. “The approval of pembrolizumab is an exciting event for patients, but clearly there’s a lot of room for improvement,” Celebi said, citing a Keynote-012 study which showed Merck’s drug achieved an 18% overall response in patients with metastatic squamous cell carcinoma of the head and neck.ĬMO Marie-Louise Fjaellskog noted in a statement: One of 9 patients evaluated at the time had a partial response, with a tumor reduction of 43%, according to the company. And at ESMO, the biotech read out early data from a Phase I/II study of the candidate and Merck’s Keytruda for advanced head and neck cancer. Last summer, Sensei joined forces with AstraZeneca to test SNS-301 in combination with Imfinzi in two Phase II trials across multiple solid tumors. That includes SNS-401, a potential vaccine cocktail against Merkel cell carcinoma, and SNS-VISTA, an antibody-based therapeutic. It will also help ready the biotech’s earlier candidates for IND applications, which could come sometime in the next 12 to 18 months. It was led by Cambrian Biopharma and H&S Ventures, and will fund the Phase II development of SNS-301. The round, which the company is calling a Series AA, follows several seed rounds, Celebi said. “Right now we’re really focused on adding additional Phase II clinical and translational data to support SNS-301,” CEO John Celebi said. The Maryland-based biotech, formerly known as Panacea, is looking to expand Phase II trials for SNS-301, an engineered inactivated bacteriophage designed to “awaken” the immune system. Less than a month after offering a glimpse at early clinical data for its lead cancer immunotherapy at virtual ESMO, Sensei Biotherapeutics has reeled in $28.5 million to wade deeper into Phase II. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |